CHOSA.ST CHOSA Oncology AB
- Market cap
- SEK 49.7M
- P/E
- -
- P/B
- 2.28x
- ROE
- -47.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CHOSA.ST undervalued?
Graham numberThe Graham number of CHOSA Oncology AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CHOSA Oncology AB fundamental analysis
No fundamental analysis for CHOSA Oncology AB yet.
CHOSA Oncology AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CHOSA Oncology AB
Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden and USA. It provides Platin-DRP, a multigene mRNA-based algorithm that predicts a patient's response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites. The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 …
Full company profileCHOSA Oncology AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CHOSA Oncology AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | 4.11M | 4.61M | 0.00 |
| Operating Income | -1.17M | -23.5M | -5.60M | -6.23M | -9.60M |
| EBITDA | -667K | -22.5M | -4.77M | -5.89M | -8.91M |
| Net Income | -1.02M | -23.9M | -4.77M | -5.61M | -9.00M |
| EPS | -0.05 | -0.35 | -0.06 | -0.07 | -0.10 |
| Balance Sheet | |||||
| Total Assets | 11.9M | 19.4M | 21.4M | 20.3M | 21.1M |
| Total Liabilities | 282K | 2.02M | 2.77M | 3.71M | 1.96M |
| Shareholders' Equity | 11.6M | 17.4M | 18.6M | 16.5M | 19.1M |
| Cash & Short-term Investments | 966K | 8.77M | 6.44M | 1.79M | 2.56M |
| Cash Flow | |||||
| Operating Cash Flow | -494K | 1.20M | -4.00M | -4.02M | -12.4M |
| Capital Expenditure | 37.0K | 0.00 | 4.11M | 4.61M | 0.00 |
| Free Cash Flow | -531K | 1.20M | -8.11M | -8.63M | -12.4M |
| Ratios | |||||
| ROE | -8.8% | -137.5% | -25.6% | -33.9% | -47.1% |
| ROA | -8.6% | -123.3% | -22.3% | -27.7% | -42.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
CHOSA Oncology AB dividends
CHOSA Oncology AB has not paid dividends in the last 4 fiscal years.
Who owns CHOSA Oncology AB
- Insiders 13.29%
- Institutions 0.00%
- Public & others 86.71%
- Shares outstanding 91.4M
- Free float 54.7M
CHOSA Oncology AB company profile
- Company name
- CHOSA Oncology AB
- Ticker
- CHOSA.ST
- Exchange
- Stockholm Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- Kungsgatan 6, Malmö, Sweden, 211 49
- Phone
- 45 2 16 08 922
- Website
- chosaoncology.com
About CHOSA Oncology AB
Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden and USA. It provides Platin-DRP, a multigene mRNA-based algorithm that predicts a patient's response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites. The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 and is based in Malmö, Sweden.
CHOSA Oncology AB management
4- Mr. Peter Buhl Jensen Adj Professor, M.D., Ph.D.Chief Executive Officer · born 1955
- Ms. Ulla Hald BuhlCOO & Board Member · born 1964
- Mr. Claus Frisenberg PedersenChief Commercial Officer & Board Member · born 1972
- Mr. Gerton JonssonChief Financial Officer · born 1971